| 1. |
- Phu, Vu Dinh, et al.
(författare)
-
Ventilator-associated respiratory infection in a resource-restricted setting: impact and etiology
- 2017
-
Ingår i: Journal of Intensive Care. - : BioMed Central (BMC). - 2052-0492. ; 5
-
Tidskriftsartikel (refereegranskat)abstract
- Ventilator-associated respiratory infection (VARI) is a significant problem in resource-restricted intensive care units (ICUs), but differences in casemix and etiology means VARI in resource-restricted ICUs may be different from that found in resource-rich units. Data from these settings are vital to plan preventative interventions and assess their cost-effectiveness, but few are available.
|
|
| 2. |
- Dinh-Xuan, Anh Tuan, et al.
(författare)
-
ERS publications: the flagship and the fleet
- 2012
-
Ingår i: European Respiratory Journal. - : European Respiratory Society (ERS). - 1399-3003 .- 0903-1936. ; 40:3, s. 535-537
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
| 3. |
- Högman, Marieann, et al.
(författare)
-
ERS technical standard : Global Lung Function Initiative reference values for exhaled nitric oxide (FENO)
- 2024
-
Ingår i: European Respiratory Journal. - : European Respiratory Society. - 0903-1936 .- 1399-3003. ; 63:1
-
Tidskriftsartikel (refereegranskat)abstract
- Elevated levels of exhaled nitric oxide at a flow of 50 mL·s-1 (FENO50) are an important indicator of Th2 airway inflammation and may aid clinicians in the diagnosis and monitoring of asthma. This study aimed to derive Global Lung Function Initiative reference equations and the upper limit of normal for FENO50Available individual FENO50 data were collated and harmonised using consensus-derived variables and definitions. Data collected from individuals who met the harmonised definition of "healthy" were analysed using generalised additive models of location shape and scale (GAMLSS) technique.Data were retrospectively collated from 34 782 individuals from 34 sites in 15 countries, of whom 8022 met the definition of healthy (19 sites, 11 countries). Overall, height, age and sex only explained 12% of the between-subject variability of FENO50 (R2=0.12). The addition of NO device was a predictor of FENO50 and between-subject variability, such that the healthy range of values and the upper limit of normal varied depending on which device was used. The range of FENO50 values observed in healthy individuals was also very wide, and the heterogeneity was partially explained by the device used. The heterogeneity between sites remained within a sub-set of data where FENO50 was measured using the same device and a stricter definition of health (n=1027).Available FENO50 data collected from different sites using different protocols and devices was too variable to develop a single all-age reference equation. Further standardisation of NO devices and measurement is required before population reference values might be derived.
|
|
| 4. |
- Högman, Marieann, et al.
(författare)
-
Utilising exhaled nitric oxide information to enhance diagnosis and therapy of respiratory disease : current evidence for clinical practice and proposals to improve the methodology
- 2017
-
Ingår i: Expert Review of Respiratory Medicine. - : Taylor & Francis Group. - 1747-6348 .- 1747-6356. ; 11:2, s. 101-109
-
Forskningsöversikt (refereegranskat)abstract
- Introduction: A non-invasive tool to diagnose respiratory diseases and to follow treatment has long been looked-for. Exhaled nitric oxide (NO) is a promising marker of inflammation in asthma but nearly 25-years of research has shown that it works in only certain endotypes of asthma. The modelling of NO dynamics of the lung can give more information than a single FENO value.Areas covered: The estimation of the NO production in the conducting airways and in the gasexchange area has given new insight of the NO production in diseases beyond asthma. In thisarticle, we discuss the importance of methodology for NO measurement in the exhaled breath and the indication of applying this technique to detect respiratory disorders. This narrative review is an attempt to examine and discuss the physiological basis underlying exhaled NO measurements and the clinical evidence of the usefulness of this method in asthma and various other respiratory disorders.Expert commentary: Estimation of the NO parameters would aid in our understanding of the NOdynamics of the lung and thereby give more knowledge how to interpret the measured FENO value in clinical practice.
|
|
| 5. |
|
|
| 6. |
- Oliveira, Ana, et al.
(författare)
-
Holistic management of patients with progressive pulmonary fibrosis
- 2023
-
Ingår i: Breathe. - 1810-6838. ; 19:3
-
Forskningsöversikt (refereegranskat)abstract
- Progressive pulmonary fibrosis (PF) is a complex interstitial lung disease that impacts substantially on patients’ daily lives, requiring personalised and integrated care. We summarise the main needs of patients with PF and their caregivers, and suggest a supportive care approach. Individualised care, education, emotional and psychological support, specialised treatments, and better access to information and resources are necessary. Management should start at diagnosis, be tailored to the patient’s needs, and consider end-of-life care. Pharmacological and non-pharmacological interventions should be individualised, including oxygen therapy and pulmonary rehabilitation, with digital healthcare utilised as appropriate. Further research is needed to address technical issues related to oxygen delivery and digital healthcare.
|
|
